Acne vulgaris - Pipeline Insight, 2021

Acne vulgaris - Pipeline Insight, 2021

  • June 2021 •
  • 70 pages •
  • Report ID: 6096824 •
  • Format: PDF
“Acne vulgaris - Pipeline Insight, 2021,” report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Acne vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Acne vulgaris Understanding

Acne vulgaris: Overview
Acne vulgaris is an inflammatory disorder of pilosebaceous unit, which runs a chronic course and it is self-limiting. It is classified into different forms which vary in severity, lesion type, and localization. It is a very common skin disorder which can present with inflammatory and non-inflammatory lesions chiefly on the face but can also occur on the upper arms, trunk, and back. Acne vulgaris is characterized by noninflammatory, open or closed comedones and by inflammatory papules, pustules, and nodules. Symptoms can be mild, moderate, or severe. Acne vulgaris is diagnosed clinically. Treatment for acne vulgaris based on severity and can involve a variety of topical and systemic agents directed at reducing sebum production, comedone formation, inflammation, and bacterial counts and at normalizing keratinization.

"Acne vulgaris - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acne vulgaris pipeline landscape is provided which includes the disease overview and Acne vulgaris treatment guidelines. The assessment part of the report embraces, in depth Acne vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acne vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Acne vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Acne vulgaris.

Acne vulgaris Emerging Drugs Chapters
This segment of the Acne vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acne vulgaris Emerging Drugs
• Twyneo: Sol-Gel Technologies
Twyneo is an investigational, antibiotic-free, fixed-dose combination of benzoyl peroxide, 3%, and tretinoin, 0.1%, cream for the treatment of acne vulgaris, using company’s own proprietary drug-delivery technology. In December 2020, Sol-Gel Technologies announced that its New Drug Application (NDA) for Twyneo for the treatment of acne vulgaris, has been accepted for filing by the U.S. Food and Drug Administration (FDA). The Prescription Drug User Fee Act (PDUFA) goal date assigned by the FDA for Twyneo is August 1, 2021.

• BOS-356: Boston Pharmaceuticals
BOS-356 is a selective DGAT1 (diacylglycerol acyltransferase 1) inhibitor. The drug is formulated for both oral and topical administration. BOS-356 decreases the synthesis of triglyceride, a major component of sebum, and reduces the size of sebaceous glands in preclinical models in vivo. Topical BOS-356 is a potential treatment for moderate to severe acne vulgaris. The drug is in Phase I clinical developmental studies for the treatment of Acne vulgaris.
Further product details are provided in the report……..

Acne vulgaris: Therapeutic Assessment
This segment of the report provides insights about the different Acne vulgaris drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Acne vulgaris
There are approx. 22+ key companies which are developing the therapies for Acne vulgaris. The companies which have their Acne vulgaris drug candidates in the most advanced stage, i.e. Preregistration include, Sol-Gel Technologies.

• Phases
This report covers around 22+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Acne vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acne vulgaris: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Acne vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acne vulgaris drugs.

Acne vulgaris Report Insights
• Acne vulgaris Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acne vulgaris Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Acne vulgaris drugs?
• How many Acne vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acne vulgaris?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acne vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acne vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Sol-Gel Technologies
• Bausch Health Companies
• AOBiome
• Boston Pharmaceuticals
• Eligo Bioscience
• Suzhou Kintor Pharmaceuticals
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
• Vicuron Pharmaceuticals
• Galderma

Key Products
• Twyneo
• IDP 126
• B 244
• BOS-356
• EB-005
• GT-20029
• Aminolevulinic acid
• NAI Acne
• Ivermectin topical